Supernus to Host First Quarter 2017 Earnings Conference Call
April 26 2017 - 4:15PM
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty
pharmaceutical company focused on developing and commercializing
products for the treatment of central nervous system (CNS)
diseases, today announced that the Company expects to report the
financial results for the first quarter of 2017 after 5:00 PM ET on
Tuesday, May 9, 2017.
Jack Khattar, President and Chief Executive Officer, and Greg
Patrick, Chief Financial Officer, will host a conference call to
present the first quarter 2017 results on Wednesday, May 10, 2017
at 9:00 AM ET. Following the presentation, the call will be open
for questions.
A live webcast will be available on the supernus.com website, in
the Investor section.
Please refer to the information below for conference call
dial-in information. Callers should dial in approximately 10
minutes prior to the start of the call.
Conference
dial-in: |
|
|
(877) 288-1043 |
International
dial-in: |
|
|
(970) 315-0267 |
Conference
ID: |
|
|
9981751 |
Conference
Call Name: |
|
|
Supernus Pharmaceuticals 1Q 2017 Earnings Conference Call |
|
|
|
|
Following the live call, a replay will be available on the
Company's website under the 'Investors' section. The webcast will
be available on the Company's website for 60 days following the
live call.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on developing and commercializing products for the
treatment of central nervous system diseases. The Company currently
markets Trokendi XR® (extended-release topiramate) for treatment of
migraine and epilepsy and Oxtellar XR® (extended-release
oxcarbazepine) for treatment of epilepsy. The Company is also
developing several product candidates to address large market
opportunities in psychiatry, including SPN-810 for the treatment of
Impulsive Aggression in ADHD patients and SPN-812 for the treatment
of ADHD.
CONTACTS:
Jack A. Khattar, President and CEO
Gregory S. Patrick, Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591
or
INVESTOR CONTACT:
Peter Vozzo
Westwicke Partners
Office: (443) 213-0505
Mobile: (443) 377-4767
Email: peter.vozzo@westwicke.com
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Sep 2023 to Sep 2024